key: cord-0836369-kcvmlpb8
authors: Hadj Hassine, Ikbel
title: Covid‐19 vaccines and variants of concern: A review
date: 2021-11-09
journal: Rev Med Virol
DOI: 10.1002/rmv.2313
sha: 9d86528df37ade7c4c2781e0ab42b2b1bbc713be
doc_id: 836369
cord_uid: kcvmlpb8

Since the outbreak of coronavirus disease 2019 (Covid‐19) in December 2019, caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the number of confirmed infections has risen to more than 242 million worldwide, with nearly 5 million deaths. Currently, nine Covid‐19 vaccine candidates based on the original Wuhan‐Hu‐1 strain are at the forefront of vaccine research. All nine had an efficacy over 50% against symptomatic Covid‐19 disease: NVX‐CoV2373 (∼96%), BNT162b2 (∼95%), mRNA‐1273 (∼94%), Sputnik V (∼92%), AZD1222 (∼81%), BBIBP‐CorV (∼79%), Covaxin (∼78%), Ad26.CoV.S (∼66%) and CoronaVac (∼51%). However, vaccine efficacy (VE) can be jeopardised by the rapid emergence and spread of SARS‐CoV‐2 variants of concern (VOCs) that could escape from neutralising antibodies and/or cell‐mediated immunity. Rare adverse events have also been reported soon after administration of viral vector and mRNA vaccines. Although many Covid‐19 vaccines have been developed, additional effective vaccines are still needed to meet the global demand. Promising Covid‐19 vaccines such as WIBP‐CorV, AD5‐nCOV, ZyCoV‐D, CVnCoV, EpiVacCorona and ZF2001 have advanced to clinical studies. This review describes the most relevant mutations in the SARS‐CoV‐2 spike protein, discusses VE against VOCs, presents rare adverse events after Covid‐19 vaccination and introduces some promising Covid‐19 vaccine candidates.

Non-pharmaceutical measures including physical distancing, proper use of masks, teleworking, isolations and quarantines have been imposed to delay the spread of Covid-19. 5, 6 However, these behavioural measures have unwanted effects, such as a negative psychological impact, major depressions and mental health consequences. 7 Developing a safe and efficient vaccine has been the only promising goal for the successful fight against Covid-19. WHO declared the global pandemic in March 2020. 8 CoV-2 variants has raised concerns related to reduced effectiveness of neutralising antibodies and/or cell-mediated immunity elicited by currently available vaccines. According to the WHO, these variants are denoted as Alpha, Beta, Gamma and Delta. 10 Rare adverse events have also been described following the immunisation with CoronaVac, AZD1222, Ad26.COV2.S, BNT162b2 and mRNA-1273. [11] [12] [13] [14] [15] [16] [17] [18] However, causal links between Covid-19 vaccines and rare adverse events have not been established.

This review describes spike mutations of interest, discusses vaccine efficacy (VE) against variants of concern (VOCs) and reports on rare adverse events occurring after Covid-19 vaccination. It also serves as an introduction to some promising Covid-19 vaccine candidates. To the best of my knowledge, this is the first paper reviewing the VE of nine different vaccine candidates against VOC, outlining severe adverse events following the immunisation with five Covid-19 vaccines and presenting some potential good vaccines in the pipeline.

SARS-CoV-2 is a spherical or pleomorphic enveloped virus with a diameter in the range of 70-110 nm containing a large unsegmented single-stranded positive-sense RNA (Figure 1a ). 19 The genome size of SARS-CoV-2 is about 29.9 kb, which is between the genome sizes of severe acute respiratory syndrome coronavirus (SARS-CoV) (∼29.7 kb) and middle east respiratory syndrome coronavirus (∼30.1 kb). 20, 21 It is composed of a 5ʹ-leader-UTRs-replicase-S-E-M-N-3ʹ UTR-poly-A tail sequence and is characterised by the presence of a variable number (6) (7) (8) (9) (10) (11) (12) of open reading frames (ORFs) between conserved genes (ORF1ab, S, E, M and N). 1 S, M, E and N genes located at the ORFs 10 and 11 encode the four structural proteins: a spike protein (S), a membrane protein (M), an envelope protein (E) and a nucleocapsid protein (N), that are responsible for viral replication and propagation (Figure 1b) . 22 In the viral envelope, the S proteins form a crown-like structure that justifies the name given to this type of viruses ('corona'). The S protein is the most immunogenic component of the virus, and therefore the most potent target of neutralising antibodies that inhibit virus infection. 20 The M protein is the largest and the most abundant structural protein, which defines the shape of the virion and plays a crucial function in the budding process of viral particles from their host cells. The E protein is essential for virus infection and replication. 20 The assembly of S, E and M proteins forms the viral coat ( Figure 1a ). The N protein is associated with the genomic RNA and maintains the genetic material inside the envelope. It is an essential protein for viral replication. During self-assembly of viral particles, the M viral protein cooperates with other structural proteins to form the complete virion. 23 

The SARS-CoV-2 S protein (Mr 180,000-200,000) is made of 1273 aa. 24 It is composed of two subunits (S1 and S2) (Figure 1c ). S1

contains an N-terminal domain and the receptor-binding domain (RBD). The 'S1 head' is responsible for receptor binding. S2 includes an internal membrane fusion peptide, two heptapeptide repeat sequences (HR1 and HR2), a membrane-proximal external region, and a transmembrane domain (TM) (Figure 1d ). 23, 25 The 'S2 filament' facilitates the entry of the genome into host cells by fusing the host and viral membranes. 26 The trimeric S protein is the main surface glycoprotein, 27 which binds to the human angiotensin-converting enzyme 2 (ACE2) for viral entry and the serine host-cell protease 2 for S protein priming. 28 Therefore, SARS-CoV-2 S glycoprotein is the most relevant source of antigens for vaccine development. 23 

Current Covid-19 vaccines have been developed by including the S protein found in the original Wuhan-hu-1 strain. However, SARS-CoV-2 is throwing out notable missense mutations within the trimeric S protein ( Figure 2 ). SARS-CoV-2 VOCs have acquired some of the potential spike protein mutations ( Table 1 ) that may increase their transmissibility and/or virulence with a possible reduction of vaccine effectiveness. [29] [30] [31] Non-synonymous mutations of particular interest that may be promoting the spread of SARS-CoV-2 include the following.

Lys417 is located in the RBD of the S glycoprotein, whichinteracts with the human ACE2 receptor protein. A non-synonymous mutation 

L452R is found in the Delta variant and refers to the amino acid change from leucine (L) to arginine (R) (Figure 2d ). This RBD mutation appears to enhance ACE2 receptor binding affinity and can diminish the interaction with vaccine-elicited antibodies. 35 Moreover, it could provide resistance to T cells, which are essential to target and destroy virus-infected cells. 36 

The amino acid substitution E484K, also known as Eeek, indicates a change from glutamic acid (E) to lysine (K) at position 484. This missense mutation is shared by Beta and Gamma VOCs. 37 Eeek could improve the capability to escape the immune system by affecting antibody recognition. As a consequence, it could alter the effectiveness of current vaccines. 38 

The amino acid substitution N501Y, nicknamed Nelly, is shared by Alpha (Figure 2a Abbreviations: VOC, variant of concern; WHO, World Health Organization. asparagine (N) to tyrosine (Y) at position 501 is believed to boost binding affinity to human ACE2. [38] [39] [40] This mutation induces higher concentrations in the pharynx and the nasal cavities, and therefore, increases its transmission rate. 41 

The missense mutation D614G, also known as Doug, denotes a change from aspartic acid (D) to glycine (G) at position 614. D614G mutation is shared by all VOCs. Studies reported that it increases the transmission rate 42,43 and leads to higher infectivity of the olfactory epithelium, therefore, induces anosmia. 44 2.3.6 | Amino acid substitutions affecting P681

P681H and P681R substitutions have been detected in Alpha and Delta, respectively. Worldwide, the prevalence of P681H has increased exponentially. 34, 45 P681R is located at the furin cleavage site and increases viral fusogenicity 46 and may be associated with a higher pathogenicity. 47 Moreover, the P681R Delta spike mutation exhibits resistance to the neutralising antibodies elicited by immunisation. 48 

Three major vaccine technology platforms are currently exploited to design safe and effective Covid-19 vaccines. These platforms are illustrated in Figure 3 and are summarised in Table 2 . 

The nucleic acid platform uses genetic information, either DNA or mRNA, to provide instructions to cells to produce specific proteins, not the entire virus. 53 No gene-based vaccines had been approved before the Covid-19 outbreak. 54

A subunit vaccine uses one or more purified antigens that can trigger the immune system. 55 April 2021, 12 US participants were reported with cerebral venous sinus thrombosis and thrombocytopenia. 12 All cases were women aged from 18 to younger than 60 years, and 25% of them died.

During the same period, four cases of anaphylaxis were also reported, but none of them resulted in death. 14 In late June 2021, 108 cases of Guillain-Barré syndrome (GBS) were also reported, and one of them resulted in death. 15 

The mRNA-1273 vaccine was developed by Moderna and the National Institute of Allergy and Infectious Diseases. The mRNA is encapsulated in lipid nanoparticles (LNPs) and encodes the full-length S antigen, with a transmembrane anchor and an S1-S2 cleavage site.

Two proline subunits were included in the S2 to stabilise the S protein in its prefusion conformation, and therefore improve its immunogenicity. 69 An interim analysis of the phase 3 clinical trial showed that the vaccine had 94.1% efficacy in preventing symptomatic infections 111 The RBD mutations found in the UK, South Africa, and Brazil variants decrease the VE by a small, but significant margin. 112 62 The mRNA is packaged in LNP and encodes the entire spike protein, modified after including two prolines in one of the subunits to stabilise the prefusion conformation and increase its immunogenicity. 117 The preliminary data from phase 2/3 clinical trials demonstrated that BNT162b2 had 95% efficacy in preventing symptomatic SARS-CoV-2 infections. 62 The quick spread of UK and South Africa variants (both encoding the N501Y substitution) is of particular concern due to their location in the RBD of the S glycoprotein. 118 Reported data showed that the neutralising activity against the novel substitution was not reduced compared to the virus carrying the original Asn501. 118 Six volunteers who received two doses of the vaccine were recruited to test the effect of BNT162b2 against VOCs encoding E484K-, N501Y-or K417N/ E484K/N501-mutant S proteins. 112 Data revealed that RBD mutations found in Alpha, Beta, and Gamma variants can decrease the efficacy of the vaccine by a small, but significant margin. 112 demonstrated that the RBD-vaccine induced high nAb titres and cytokines associated with T-helper 1 and T-helper 2 cells. 127 Recent data showed that RBD-vaccine retained neutralising effects against Beta and Gamma variants and preserved its neutralising activity against Delta strain. 143 Rare adverse events have also been reported following Covid-19

immunisation -including TTS, anaphylaxis, myocarditis, and GBS.

Although Ad26.CoV.S vaccine alleviates all these rare side effects, anaphylaxis and myocarditis mainly occur after immunisation with mRNA-Based vaccines, and thrombosis thrombocytopenia syndrome is associated with adenoviral vector-based vaccines. More research is needed to fully understand the link between Covid-19 vaccines and rare side effects and long-term investigation is further required to assess delayed reactions to immunisation.

The author would like to acknowledge Dr Luis Menéndez-Arias (CSIC-CBMSO) for critically reading the manuscript. No funding was received for this study.

The author declares that there is no conflict of interest.

The author confirms sole responsibility for the following: study conception and design, data collection and processing, analysis and interpretation of results, and manuscript preparation.

All data used are available in this review.

Ikbel Hadj Hassine https://orcid.org/0000-0003-1992-7976

A novel coronavirus from patients with pneumonia in China

Covid-19: a brief overview of the discovery clinical trial

The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Naming the coronavirus disease (COVID-19) and the virus that causes it

Global public health COVID-19 vaccines and treatments nationalism: challenges for low-income countries and the attainment of the SDGs

Access to COVID-19 vaccines and medicines-a Global Public Good Zur Verfügung Gestellt in Kooperation Mit/ provided in cooperation with: GIGA German Institute of Global and Area Studies Vaccines and Medicines -a Global Public Good. (GIGA Focus Global, 4)

Mental health and the covid-19 pandemic

WHO declares COVID-19 a pandemic

COVID-19 vaccine tracker and landscape

Tracking SARS-CoV-2 variants

Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination

US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination

EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines

safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine -United States

COVID-19 Vaccine Janssen: Guillain-Barré Syndrome Listed as a Very Rare Side Effect. European Medicines Agency

Pityriasis rosea following CoronaVac COVID-19 vaccination: a case report

Reactive arthritis after COVID-19 vaccination

Myocarditis and pericarditis after mRNA COVID-19 vaccination

Electron microscopy of SARS-CoV-2: a challenging task

One year update on the COVID-19 pandemic: where are we now?

SARS and MERS: recent insights into emerging coronaviruses

Origin and evolution of pathogenic coronaviruses

Current advances in the development of SARS-CoV-2 vaccines

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

Structure, function, and evolution of coronavirus spike proteins

Structure analysis of the receptor binding of 2019-nCoV

A review of the progress and challenges of developing a vaccine for COVID-19

Structural insights into coronavirus entry

The proximal origin of SARS-CoV-2

The 2019-new coronavirus epidemic: evidence for virus evolution

A pneumonia outbreak associated with a new coronavirus of probable bat origin

The N501Y and K417N mutations in the spike protein of SARS-CoV-2 alter the interactions with both hACE2 and human derived antibody: a free energy of perturbation study

Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: an insight from structural data

A tale of three SARS-CoV-2 variants with independently acquired P681H mutations in New York State

Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein 1 triggers recent massive expansion of SARS-Cov-2 variants 2

Identification of a SARS-CoV-2 variant with L452R and E484Q neutralization resistance mutations

Covid-19: what new variants are emerging and how are they being investigated?

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

Distinct patterns of emergence of SARS-CoV-2 spike variants including N501Y in clinical samples in Columbus Ohio

Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the Severe acute respiratory syndrome coronavirus 2 501Y Variant 1 and Variant 2

The British variant of the new coronavirus-19 (SARS-CoV-2) should not create a vaccine problem

Origin, evolution and global spread of SARS-CoV-2

D614G mutation of SARS-CoV-2 spike protein enhances viral infectivity

Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus

Genetic Characteristics and Phylogeny of 969-bp S Gene Sequence of SARS-CoV-2 from Hawai'i Reveals the Worldwide Emerging P681H Mutation FDA = Food and Drug Administration VOC = Variant of Concern VTM = Viral Transport Media

Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant

SARS-CoV-2 spike P681R mutation enhances and accelerates viral fusion

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

Influenza vaccine: where are we and where do we go

Polio vaccination: past, present and future

Safety and immunogenicity of novel adenovirus type 26-and modified vaccinia Ankaravectored Ebola vaccines: a randomized clinical trial

Ebola vaccine trials: progress in vaccine safety and immunogenicity

A comparison of plasmid DNA and mRNA as vaccine technologies

RNA vaccines: a suitable platform for tackling emerging pandemics? Front Immunol

Characterization of Coxsackievirus B4 virus-like particles VLP produced by the recombinant baculovirus-insect cell system expressing the major capsid protein

Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis b vaccine with a novel adjuvant

Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Safety and efficacy of singledose Ad26.COV2.S vaccine against covid-19

Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine

Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine

The arrival of Sputnik V

COVID vaccine excitement builds as Moderna reports third positive result

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Artic Lancet Infect Dis

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults

Safety and immunogenicity of two RNA-based covid-19 vaccine candidates

Safety and efficacy of NVX-CoV2373 covid-19 vaccine

Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2

Development of an inactivated vaccine candidate for SARS-CoV-2

Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques

Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS-CoV-2 vaccine candidates in the Syrian hamster model. iScience

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques

Early-stage trial data on AstraZeneca COVID-19 vaccine due Monday -Lancet. Race for a cure

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates

A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in

Brazil: the PROFISCOV study

Interim results of a phase 1-2a trial of Ad26.COV2.S covid-19 vaccine

An mRNA vaccine against SARS-CoV-2 -preliminary report

Antibody and T cell responses to Sinopharm/BBIBP-CorV in naïve and previously infected individuals in Sri Lanka. medRxiv

Susceptibility of circulating SARS-CoV-2 variants to neutralization

Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac

Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study

Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine 1 (BBV152): a, double-blind, randomised

Levels of SARS-CoV-2 lineage P.1 neutralization by antibodies elicited after natural infection and vaccination

Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2

Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152. bioRxiv

Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine

Effectiveness of covid-19 vaccines against the B.1.617.2 (Delta) variant

Effectiveness of the ChAdOx1 vaccine in the elderly during SARS-CoV-2 Gamma variant transmission in Brazil. medRxiv

Efficacy of the ChAdOx1 nCoV-19 covid-19 vaccine against the B.1.351 variant

Sweden joins Germany, France, and 15 other countries in suspending AstraZeneca's vaccine over possible side effects

Expert suspects causal link between AstraZeneca jab and rare blood clots

Prothrombotic immune thrombocytopenia after COVID-19 vaccine

COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern

A one-shot COVID-19 vaccine

Thrombotic thrombocytopenia after Ad26.COV2.S vaccination -response from the manufacturer

COVID-19 vaccine-induced myocarditis: case report with literature review

Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Res Sq

Russia's Sputnik V shot around 90% effective against Delta variant, developers say. Reuters

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

Serum neutralizing activity of mRNA-1273 against SARS-CoV-2 variants

Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine -United States

RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera

A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses

Effectiveness of the BNT162b2 covid-19 vaccine against the B.1.1.7 and B.1.351 variants

BNT162b2 vaccination in people over 80 years of age induces strong humoral immune responses with cross neutralisation of P.1 Brazilian variant

COVID-19 vaccine and myocarditis

Efficacy of NVX-CoV2373 covid-19 vaccine against the B.1.351 variant

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-inhuman trial

Zydus receives EUA from DCGI for ZyCoV-D, the only needle-free COVID vaccine in the world

A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the "EpiVacCorona" vaccine for the prevention of COVID-19

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, doubleblind, placebo-controlled, phase 1 and 2 trials

CureVac's mRNA-based vaccine candidate against COVID-19. CureVac; 2021

Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials

Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models

Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models

Assessment of immunogenicity and protective efficacy of ZyCoV-D DNA vaccine candidates in Rhesus macaques against SARS-CoV-2 infection

mRNA vaccine CVnCoV protects nonhuman primates from SARS-CoV-2 challenge infection

mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents

Optimization of non-coding regions improves protective efficacy of an mRNA SARS-CoV-2 vaccine in nonhuman primates

Immunogenicity and protectivity of the peptide vaccine against SARS-CoV-2

Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India-NC-ND license. EClini-calMedicine

Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

China's single-dose COVID vaccine has efficacy similar to Johnson & Johnson's. Fortune

s first COVID-19 vaccine for those above 12, gets nod. The Hindu

Efficacy and Safety of the CVnCoV SARS-CoV-2 mRNA Vaccine Candidate: Results from Herald, a Phase 2b/3, randomised, observer-blinded, placebocontrolled clinical trial in ten countries in Europe and Latin America

Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants

How to cite this article: Hadj Hassine I. Covid-19 vaccines and variants of concern: A review